Anti-secretogranin III (SCG3) antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-11414482-B2
Application number	US-201716347668-A
Country	US
Kind code	B2
Filing date	Nov 6, 2017
Priority date	Nov 8, 2016
Publication date	Aug 16, 2022
Grant date	Aug 16, 2022

Abstract

Antibodies specific for secretogranin III (Scg3) are disclosed. Methods of using the antibodies, antigen-binding fragments thereof, or pharmaceutical compositions comprising the same in the treatment of diseases such as diabetic retinopathy, neovascular age-related macular degeneration, retinopathy of prematurity, and cancer, are also disclosed.

First claim

What is claimed:

1. An antibody or antigen-binding fragment thereof that binds secretogranin Ill, wherein the antibody or antigen-binding fragment comprises the following CDR sequences:
(i) (a) CDR-H1 comprises SEQ ID NO: 3; (b) CDR-H2 comprises SEQ ID NO: 4; (c) CDR-H3 comprises SEQ ID NO: 5; (d) CDR-L1 comprises SEQ ID NO: 6; (e) CDR-L2 comprises SEQ ID NO: 7; and (f) CDR-L3 comprises SEQ ID NO: 8;
(ii) (a) CDR-H1 comprises SEQ ID NO: 11; (b) CDR-H2 comprises SEQ ID NO: 12; (c) CDR-H3 comprises SEQ ID NO: 13; (d) CDR-L1 comprises SEQ ID NO: 14; (e) CDR-L2 comprises SEQ ID NO: 15; and (f) CDR-L3 comprises SEQ ID NO: 16;
(iii) (a) CDR-H1 comprises SEQ ID NO: 19; (b) CDR-H2 comprises SEQ ID NO: 20; (c) CDR-H3 comprises SEQ ID NO: 21; (d) CDR-L1 comprises SEQ ID NO: 22; (e) CDR-L2 comprises SEQ ID NO: 23; and (f) CDR-L3 comprises SEQ ID NO: 24;
(iv) (a) CDR-H1 comprises SEQ ID NO: 27; (b) CDR-H2 comprises SEQ ID NO: 4; (c) CDR-H3 comprises SEQ ID NO: 28; (d) CDR-L1 comprises SEQ ID NO: 22; (e) CDR-L2 comprises SEQ ID NO: 29; and (f) CDR-L3 comprises SEQ ID NO: 24;
(v) (a) CDR-H1 comprises SEQ ID NO: 27; (b) CDR-H2 comprises SEQ ID NO: 4; (c) CDR-H3 comprises SEQ ID NO: 28; (d) CDR-L1 comprises SEQ ID NO: 32; (e) CDR-L2 comprises SEQ ID NO: 29; and (f) CDR-L3 comprises SEQ ID NO: 24; or
(vi) (a) CDR-H1 comprises SEQ ID NO: 3; (b) CDR-H2 comprises SEQ ID NO: 4; (c) CDR-H3 comprises SEQ ID NO: 28; (d) CDR-L1 comprises SEQ ID NO: 22; (e) CDR-L2 comprises SEQ ID NO: 29; and (f) CDR-L3 comprises SEQ ID NO: 24.

2. The antibody or antigen-binding fragment thereof of claim 1 , comprising (i) a heavy chain variable region comprising SEQ ID NO: 1 and a light chain variable region comprising SEQ ID NO: 2; (ii) a heavy chain variable region comprising SEQ ID NO: 9 and a light chain variable region comprising SEQ ID NO: 10; (iii) a heavy chain variable region comprising SEQ ID NO: 17 and a light chain variable region comprising SEQ ID NO: 18; (iv) a heavy chain variable region comprising SEQ ID NO: 25 and a light chain variable region comprising SEQ ID NO: 26; (v) a heavy chain variable region comprising SEQ ID NO: 30 and a light chain variable region comprising SEQ ID NO: 31; (vi) a heavy chain variable region comprising SEQ ID NO: 38 and a light chain variable region comprising SEQ ID NO: 33; or (vii) a heavy chain variable region comprising SEQ ID NO: 34 and a light chain variable region comprising SEQ ID NO: 35.

3. The antibody or antigen-binding fragment thereof of claim 1 , comprising (i) a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 1 and a light chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 2; (ii) a heavy chain variable region comprising an amino acid sequence at least 90% identical SEQ ID NO: 9 and a light chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 10; (iii) a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 17 and a light chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 18; (iv) a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 25 and a light chain variable region comprising an amino acid sequence at least 90% identical SEQ ID NO: 26; (v) a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 30 and a light chain variable region comprising an amino acid sequence at least 90% identical SEQ ID NO: 31; (vi) a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 38 and a light chain variable region comprising an amino acid sequence at least 90% identical SEQ ID NO: 33; or (vii) a heavy chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 34 and a light chain variable region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 35.

4. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 and a physiologically acceptable diluent, excipient or carrier.

5. A method of treating neovascular age-related macular degeneration, diabetic retinopathy, or retinopathy of prematurity in a subject in need thereof comprising administering a therapeutically effective amount of the antibody or antigen-binding fragment thereof of claim 1 .

6. The method of claim 5 , wherein the antibody or antigen-binding fragment thereof is administered in an amount effective to inhibit choroidal neovascularization or polypoidal choroidal vasculopathy.

7. The method of claim 5 , wherein the antibody or antigen-binding fragment thereof is administered in an amount from about 5 μg/kg to about 400 mg/kg body weight of the subject.

8. The method of claim 5 , wherein the antibody or antigen-binding fragment thereof is administered to the eye of the subject in an amount from about 0.05 mg to about 10 mg.

Assignees

• Univ Miami

Inventors

• Li Wei
• Leblanc Michelle E
• Wang Weiwen
• Rosenfeld Philip J

Classifications

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61P27/02 Primary

  Ophthalmic agents · CPC title